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Abstract: Cutaneous melanoma (CM) is the most lethal tumor among skin cancers, and its incidence
is constantly increasing. A deeper understanding of the molecular processes guiding melanoma
pathogenesis could improve diagnosis, treatment and prognosis. MicroRNAs play a key role in
melanoma biology. Recently, next generation sequencing (NGS) experiments, designed to assess
small-RNA expression, revealed the existence of microRNA variants with different length and sequence. These microRNA isoforms are known as isomiRs and provide an additional layer to the
complex non-coding RNA world. Here, we collected data from NGS experiments to provide a comprehensive characterization of miRNA and isomiR dysregulation in benign nevi (BN) and early-stage
melanomas. We observed that melanoma and BN express different and specific isomiRs and have
a different isomiR abundance distribution. Moreover, isomiRs from the same microRNA can have
opposite expression trends between groups. Using The Cancer Genome Atlas (TCGA) dataset of skin
cancers, we analyzed isomiR expression in primary melanoma and melanoma metastasis and tested
their association with NF1, BRAF and NRAS mutations. IsomiRs differentially expressed were identified and catalogued with reference to the canonical form. The reported non-random dysregulation of
specific isomiRs contributes to the understanding of the complex melanoma pathogenesis and serves
as the basis for further functional studies.
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Malignant cutaneous melanoma (CM) results from transformation of pigments-producing
cells known as melanocytes. Worldwide incidence of melanoma has progressively increased
over the last several decades, reaching an age-standardized rate of 3.4 per 100,000. However,
in fair-skinned population regions, including Australia-New Zealand, Northern Europe and
Northern America, this rate exceeds 15 per 100,000 (35.8, 17.8 and 16.1, respectively) (source
IARC 2020).
Although malignant melanoma accounts only 3–5% of all skin cancers, it is the most
lethal form, and determines up to 65% of the deaths [1]. The pathogenesis of melanoma
is complex, and the onset of melanoma has been associated with several risk factors that
include genetic, environmental, and phenotypic factors such as ultraviolet (UV) exposure, fair phototypes, multiple dysplastic nevi and a positive family/personal history of
cutaneous melanoma [2].
Melanoma risk is increased in people harboring specific germline genetic alterations [3],
which include mutations in Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) gene [4,5], Cyclin Dependent Kinase 4 (CDK4), Telomerase Reverse Transcriptase (TERT), Microphthalmiaassociated transcription (MITF), BRCA1-associated protein-1 (BAP1), and Protection of
telomeres 1 (POT1) [6]. Sporadic cutaneous melanoma is characterized by one of the highest
tumor mutation rates, mainly due to UV exposure [7]. The most frequently mutated genes
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in sporadic melanoma are B-Raf Proto-Oncogene (also known as v-Raf murine sarcoma
viral oncogene homolog B, BRAF), neuroblastoma RAS viral oncogene homolog (N-RAS),
Neurofibromin 1 (NF1), proto-oncogene receptor tyrosine kinase (KIT) and Phosphatase
and Tensin homolog (PTEN) [8]. Based on the pattern of mutated genes, a genomic classification of melanoma has been established and melanomas have been classified into four
subtypes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type) [9].
The gain-of function mutations of BRAF and NRAS lead to constitutive activation of
the signaling of the mitogen-activated protein kinase (MAPK) pathway and thus to tumor
proliferation and progression [10]. On the other hand, the loss-of function of NF1 leads
to hyperactivation of RAS proteins and to promotion of MAPK pathway signaling [11].
The discovery that BRAF and NRAS mutations are two of the main oncogenic drivers of
melanoma proliferation and survival has resulted in important therapeutic implications
and changed the management of cutaneous melanoma patients with the development of
specific targeted therapies based on MAPK pathway inhibitors [12].
Important molecular factors in melanoma pathogenesis are microRNAs (miRNAs).
miRNAs are small non-coding RNAs (18–22 nucleotides in length) that regulate multiple
pathways with an oncogenic or tumor suppressive role [13–15]. Normal and pathological
cells and tissues can be classified using the global miRNA expression profile [16,17].
In the past decade, the characterization of the tissue miRNA profile has taken advantage of the spreading of deep sequencing techniques to investigate the sequence and
abundance of small noncoding RNAs. Most small RNA sequencing studies focused
on the identification of canonical miRNAs, whose sequence is reported in the miRBase
database [18]. Recently, many deep sequencing experiments in human tissues evidenced
the existence of alterations in miRNA length and sequence [19], suggesting the importance
of including the analysis of miRNA variants or isoforms (isomiRs) in miRNA studies.
The isomiR biogenesis has not been completely clarified yet, but it seems that isomiRs
could derive from alternative Drosha and or Dicer cleavage of the precursor miRNAs [20],
or from post-transcriptional modifications made by nucleotidyl transferase, which adds
nucleotides to the pre-miRNA or mature miRNA ends [21–23]. Stability and abundance
can vary between the canonical miRNA and its isoforms. The proposed role of isomiRs is
to reinforce the regulatory activity of canonical miRNAs [24], though there is still much to
discover. Furthermore, isomiR expression can discriminate human cancers [25].
Recently, we investigated the global canonical miRNA profile of formalin-fixed paraffinembedded (FFPE) samples of benign nevi, single and multiple primary melanomas [26]. In
addition, we analyzed the smallRNA sequencing data at the isomiR level. Combining all the
samples together, we identified a panel of highly expressed isomiRs, with an expression up to
10 times higher than the canonical miRNA.
This prompted us to further investigate the contribution of isomiRs in melanoma
progression. Specifically, in this study we identify and classify isomiRs detectable in FFPE
benign nevi and melanoma samples using proprietary small RNA sequencing data and
assess isomiR expression in relation to the corresponding canonical miRNA. In addition,
we compare the isomiR expression profile of benign nevus and melanoma. Finally, using
publicly available smallRNA sequencing data from fresh-frozen skin cutaneous melanoma
(SKCM) of The Cancer Genome Atlas (TCGA) database, we identify and compare the
isomiR expression profile of primary melanoma and metastasis, and identify isomiRs
whose expression is associated with NF1, BRAF and NRAS mutations.
In what follows, the term “canonical” has been used to indicate the sequence of a
microRNA as reported in miRBase. On the other hand, “isomiRs”, “miRNA variants” and
“miRNA isoforms” indicates all the variant forms that differentiate from the canonical
miRNA. Finally, the set of canonical miRNAs and their isomiRs has been grouped and
called “mature microRNAs”.
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2. Results
2.1. Mature microRNA Profile and miRNA Variants Characterization in Early-Stage
Melanoma Samples
We analyzed the global mature microRNA (canonical and isomiR) profile of 23 FFPE
samples: three benign nevi (BN) and 20 early-stage primary cutaneous melanoma (CM)
samples [26]. Using a dedicated bioinformatics pipeline called isoMiRmap [27], we identified 494 mature microRNAs, including 130 canonical miRNAs and 364 microRNA isoforms
that passed quality trimming and filtering. Specifically, we identified 90 canonical miRNAs
with at least one isomiR, for a total of 324 isomiRs with a detectable canonical form. About
28% of these 90 canonical miRNAs had only one isomiR, 30% had two or three isomiRs and
the remained 42% consisted in miRNAs that had a number of isomiRs that ranged from
four to thirteen (Table 1, Figure 1A). The characterization of all mature miRNAs evidenced
that 40 expressed canonical miRNAs did not have any isomiR in our data. As a counterpart,
canonical miRNA sequences were not detected in our dataset for about 11% of the identified
isomiRs. In this case, isomiRs are called “orphan” isomiRs (Supplementary Table S1).
Table 1. Mature microRNA classification in 23 formalin-fixed paraffin-embedded (FFPE) samples.
Mature miRNAs from Small RNA Seq of FFPE Samples
Type
“canonical” miRNA

isomiR

Sub-type

Total

miRNA with isomiR(s)

90 (18.2%)

miRNA without isomiR

40 (8.1%)

isomiR with canonical miRNA

324 (65.6%)

orphan isomiR

40 (8.1%)

130 (26.3%)

364 (73.7%)

Total

494 (100%)

Classification of canonical miRNAs with isomiR(s)
Groups

Sub-groups

miRNA with 1 isomiR

Total
25 (27.8%)

miRNA with 2–3 isomiRs

miRNA with 4–5 isomiRs

miRNA with 6–13 isomiRs

2 isomiRs

14 (15.6%)

3 isomiRs

13 (14.4%)

4 isomiRs

10 (11.1%)

5 isomiRs

11 (12.2%)

6 isomiRs

6 (6.7%)

7 isomiRs

2 (2.2%)

8 isomiRs

2 (2.2%)

9 isomiRs

3 (3.4%)

10 isomiRs

2 (2.2%)

11 isomiRs

1 (1.1%)

13 isomiRs

1 (1.1%)

25 (27.8%)
27 (30.0%)

21 (23.3%)

17 (18.9%)

Total

90 (100%)

Classification of isomiRs with canonical miRNA
Groups

Sub-groups

Total

End-site isomiR

199 (61.4%)

199 (61.4%)

Start-site isomiR

19 (5.9%)

19 (5.9%)

Shifted isomiR

9 (2.8%)

9 (2.8%)

30 non-templated addition isomiR

43 (13.2%)

43 (13.2%)

End-site + start-site
Mixed isomiR

End-site +

30

non-templated addition

Start-site +

30

non-templated addition

Shifted + 30 non-templated addition
Total

13 (4.0%)
34 (10.5%)

54 (16.7%)

6 (1.9%)
1 (0.3%)
324 (100%)
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Figure 1. Mature microRNAs classification and nomenclature. (A) Classification of all mature microRNAs detected by
small-RNA sequencing in 23 formalin-fixed paraffin-embedded (FFPE) samples (20 cutaneous melanoma (CM) and 3 benign
nevi (BN)). A sunburst chart represents the type of mature microRNAs detected in small-RNA seq data. (B) Example of
mature microRNA nomenclature of miR-143-3p. miR-143 stem loop originates two canonical miRNAs, namely miR-143-5p
and miR-143-3p. In our analysis, nine mature microRNAs of miR-143-3p were detected. The table reports nomenclature,
sequence and type of mature microRNA. Nucleotides in bold corresponds to additional nucleotides compared to the
canonical sequence; “-“ indicates the deletion of a nucleotide compared to the canonical sequence.

Since isomiR sequences differentiate from canonical miRNAs in different ways, we
classified them into five categories: start-site isomiR, end-site isomiR, 30 non-templated
addition isomiR, shifted isomiR and the remaining “mixed” isomiR. The first and second
groups present nucleotides addition or deletion respectively at the 50 and at the 30 end
of the canonical sequence. In these two groups, added nucleotides “match” with the
sequence of the stem loop. On the contrary, when the added nucleotides in 50 or 30 end
are different compared to those in the stem loop sequence, we defined 50 non-templated
addition and 30 non-templated addition isomiRs, respectively. In our dataset, we did not
identify any 50 non-templated addition isomiR. Conversely, several isomiRs present 30
non-templated addition and most of them consist in uridylation, namely addition of one
or more uracils. Shifted isomiRs are long as the canonical counterpart, however their
start-sites and, consequently, their end-sites are shifted to the left (in 50 direction) or to the
right (in 30 direction) to one or more positions. Finally, the mixed isomiR group includes
isomiRs that manifest at least two of these differences compared to the canonical form. An
example of isomiR classification is reported in Figure 1B.
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2.2. End-Site isomiRs Are the Most Abundant and Expressed isomiRs in FFPE Samples
Most of the detected isomiRs belonged to the end-site class of isomiRs (61.4%), while
the other four classes were less represented. In addition, looking at the mixed group,
we observed a prevalence of isomiRs that present the combination of different end-site
modifications (deletions or additions of “matched” nucleotides) and 30 non-templated
additions when compared to canonical miRNA (Table 1).
Looking at the normalized expression of the 364 isomiRs in the 20 FFPE early-stage
melanoma samples, we observed that they can vary between 5–6 to over 2300. We selected
the most expressed isomiRs in these 20 CM samples (normalized expression >20) and
obtained a list of 126 isomiRs that are reported in Supplementary Table S2. We found that
the majority of expressed isomiRs (about 75%) belong to the end-site group. Less frequent
are the isomiRs belonging to the other groups: 9% mixed group, 9% 30 non-template
addition group, 4% start-site group and 3% shifted group.
Among the ten most expressed isomiRs we found nine end-site isomiRs (hsa-miR10b-5p|0|−1, hsa-miR-205-5p|0|+1, hsa-miR-27b-3p|0|−1, hsa-miR-125a-5p|0|−2, hsamiR-10a-5p|0|−1, hsa-miR-181a-5p|0|−1, hsa-miR-30d-5p|0|+2, hsa-miR-143-3p|0|−1,
hsa-let-7a-5p|0|−1) and one 30 non-template addition isomiR (hsa-miR-143-3p|0|0(+1U)).
2.3. Identification of isomiRs More Expressed Than the Canonical Form in Early-Stage Melanoma
To identify the most relevant isomiRs in early-stage melanoma, we focused on isomiRs
that showed a higher or an equal expression level than the corresponding canonical mRNA
form. For this purpose, we calculated the expression ratio between isomiRs and canonical
miRNA. For this analysis, we excluded miRNAs without isomiRs and orphan isomiRs. We
considered the average expression of the selected 412 mature miRNAs in 20 early-stage
melanomas and calculated the expression ratio for each isomiR. We obtained a wide set
of ratios: some isomiRs are expressed up to 3000 times less than the canonical miRNAs,
as expected, but some isomiRs are upregulated up to 50 times more than their canonical
counterparts (Supplementary Table S3).
We decided to filter our results in order to identify isomiRs that could play a role
in melanoma pathogenesis. We selected isomiRs with a ratio isomiR/miRNA >1 from
Supplementary Table S3, obtaining a list of 39 isomiRs (Figure 2A). Some of these isomiRs
belonged to the same miRNA family. Specifically, nine isomiRs belong to miR-30 family
(3 tomiR-30a-5p, 3 to miR-30d-5p and 1 to miR-30c-5p); five isomiRs belong to miR-221/222
family (3 to miR-221-3p, 2 to miR-222-3p); four isomiRs belong to miR-10 family (2 to miR125a-5p, 1 to miR-10a-5p, 1 to miR-10b-5p) three isomiRs belong to miR-101 family (all to
miR-101-3p), three isomiRs belong to miR-200 family (2 to miR-200b-3p, 1 to miR-141-3p),
and three isomiRs belong to miR-27 family (2 to miR-27b-3p, 1 to miR-27a-3p) (Table 2).
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Figure 2. Expression of mature microRNAs in FFPE samples. (A) IsomiR/canonical miRNA expression in 20 FFPE
melanoma samples. Bar graph representing isomiR/miRNA ratios in 20 FFPE early-stage melanoma samples greater than 1
for isomiR with an average normalized expression >20 (n = 39). (B) List of 55 mature microRNAs differently expressed in 20
FFPE early-stage melanoma compared to 3 FFPE benign nevi samples. Interleaved bar charts showing the average log fold
change in CM vs. BN. We identified 10 upregulated (in red) and 45 downregulated mature microRNAs with Fold change >2
and adjusted p value < 0.05.
Table 2. List of isomiRs in 20 FFPE melanoma samples with an isomiR/canonical miRNA ratio greater than 1.
Mature microRNA Name

Normalized Expression
isomiR (Average, n = 20)

Normalized Expression
Canonical miRNA (Average, n = 20)

Ratio isomiR/Canonical
miRNA

hsa-miR-222-3p|0|+3

170.56

3.17

53.84

hsa-miR-141-3p|0|−1

127.96

4.26

30.01

hsa-miR-30a-5p|0|+2

234.85

10.41

22.55

hsa-miR-222-3p|0|+4

48.31

3.17

15.25

hsa-miR-222-3p|0|+2

38.26

3.17

12.08

hsa-miR-30d-5p|0|+2

462.00

39.70

11.64

hsa-miR-200b-3p|0|+1

44.59

4.29

10.39

hsa-miR-125a-5p|0|−2

623.96

60.29

10.35

hsa-miR-30c-5p|0|+1

153.33

15.63

9.81

hsa-miR-200b-3p|0|+1(+1U)

33.28

4.29

7.76

hsa-miR-10b-5p|0|−1

2368.09

365.48

6.48

hsa-miR-30a-5p|0|−2

57.72

10.41

5.54

hsa-miR-19b-3p|0|−1

25.74

4.85

5.31

hsa-miR-199a-3p|0|−1

258.78

52.96

4.89
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Table 2. Cont.
Mature microRNA Name

Normalized Expression
isomiR (Average, n = 20)

Normalized Expression
Canonical miRNA (Average, n = 20)

Ratio isomiR/Canonical
miRNA

hsa-miR-26b-5p|0|+1

165.47

35.93

4.61

hsa-miR-30a-5p|0|+1

46.17

10.41

4.43

hsa-miR-27a-3p|0|−1

100.82

24.74

4.08

hsa-miR-30d-5p|0|+1

135.04

39.70

3.40

hsa-miR-221-3p|0|−1

39.05

11.80

3.31

hsa-miR-10a-5p|0|−1

594.23

197.37

3.01

hsa-miR-744-5p|0|−1

24.67

9.36

2.63

hsa-miR-30a-5p|0|−1

23.98

10.41

2.30

hsa-miR-27b-3p|0|−1

845.19

368.31

2.29

hsa-miR-101-3p|0|0(+1U)

47.54

21.42

2.22

hsa-miR-221-3p|0|−2

26.12

11.80

2.21

hsa-miR-509-3p|0|+1

88.74

40.27

2.20

hsa-miR-203a-3p|+1|0(+1U)

268.82

134.91

1.99

hsa-miR-101-3p|0|+1

39.31

21.42

1.83

hsa-miR-199a-3p|−1|−1

87.92

52.96

1.66

hsa-miR-29a-3p|0|−1

33.98

21.58

1.57

hsa-miR-30d-5p|0|−2

61.55

39.70

1.55

hsa-miR-203a-3p|0|+1

189.30

134.91

1.40

hsa-miR-142-5p|−2|−3

97.82

76.36

1.28

hsa-miR-125a-5p|0|−3

73.56

60.29

1.22

hsa-miR-205-5p|0|+1

1221.77

1044.60

1.17

hsa-miR-30d-5p|0|−1

45.81

39.70

1.15

hsa-miR-101-3p|−1|−1

23.09

21.42

1.08

hsa-miR-146b-5p|0|+1

35.42

33.14

1.07

hsa-miR-27a-3p|0|−2

25.16

24.74

1.02

2.4. Benign Nevi and Early-Stage Melanoma Present a Different Mature microRNA
Expression Profile
We compared the mature miRNA (canonical and isomiR) expression profile of 3 benign
nevi and 20 early-stage primary cutaneous melanoma. We identified 55 mature miRNAs
that are differentially expressed between early-stage CM and BN (adjusted p < 0.05, Table 3).
Their fold change is represented with a horizontal histogram graph in Figure 2B. Most of
them (n = 45) are downregulated in melanoma, while 10 are upregulated.
Among the differentially expressed mature miRNAs, we found 18 canonical miRNAs
and 37 isomiRs. Among the canonical miRNAs, 10 have at least one isomiR in this list
of 55 mature miRNAs ((let-7b-5p, miR-101-3p, miR-143-3p, miR-148a-3p, miR-199a-3p,
miR-199a-5p, miR-27a-3p, miR-27b-3p, miR-29a-3p, miR-99b-5p), while 8 do not have
any isomiR in the list (miR-125b-5p, miR-181a-2-3p, miR-192-5p, miR-205-5p, miR-28-3p,
miR-30b-5p, miR-497-5p, miR-99a-5p). For 16 isomiRs the canonical miRNA is not present
in the list, meaning that the isomiR is differently expressed in early-stage CM vs. BN, but
not the canonical miRNA.
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Table 3. List of differentially expressed mature microRNAs in 20 FFPE early-stage melanoma (CM) and 3 FFPE benign
nevus (BN) samples.
Mature miRNAs Differently Expressed in FFPE Samples: CM vs. BN
Name

p Value (Corr)

Regulation

Log FC

Canonical miRNAs
hsa-let-7b-5p|0|0

1.0E-02

up

2.73

hsa-miR-205-5p|0|0

9.3E-03

up

2.04

hsa-miR-143-3p|0|0

4.2E-02

up

1.50

hsa-miR-27a-3p|0|0

7.1E-03

down

−1.60

hsa-miR-192-5p|0|0

3.9E-02

down

−1.61

hsa-miR-99a-5p|0|0

2.1E-02

down

−1.77

hsa-miR-99b-5p|0|0

3.6E-02

down

−1.94

hsa-miR-28-3p|0|0

1.1E-02

down

−1.99

hsa-miR-181a-2-3p|0|0

5.8E-04

down

−2.05

hsa-miR-497-5p|0|0

3.4E-04

down

−2.27

hsa-miR-148a-3p|0|0

2.7E-03

down

−2.29

hsa-miR-30b-5p|0|0

3.3E-03

down

−2.47

hsa-miR-199a-3p|0|0

1.5E-05

down

−3.07

hsa-miR-101-3p|0|0

4.2E-05

down

−3.08

hsa-miR-199a-5p|0|0

8.9E-07

down

−3.21

hsa-miR-27b-3p|0|0

3.2E-06

down

−3.38

hsa-miR-125b-5p|0|0

9.6E-07

down

−3.98

hsa-miR-29a-3p|0|0

8.6E-09

down

−6.42

isomiRs
hsa-let-7b-5p|0|+1

5.6E-03

up

2.54

hsa-miR-30d-5p|0|+2

7.2E-03

up

2.25

hsa-miR-30a-5p|0|+2

1.3E-03

up

2.17

hsa-miR-222-3p|0|+3

9.0E-03

up

2.00

hsa-miR-143-3p|0|0(+1U)

2.6E-02

up

1.71

hsa-miR-143-3p|0|−1

4.5E-02

up

1.70

hsa-miR-203a-3p|+1|0(+1U)

4.2E-02

up

1.46

hsa-miR-199a-3p|+1|−1

2.0E-02

down

−1.19

hsa-miR-30a-5p|0|−1

1.7E-02

down

−1.28

hsa-miR-30a-5p|0|−2

4.5E-02

down

−1.36

hsa-miR-26a-5p|+3|0

4.3E-02

down

−1.44

hsa-miR-103a-3p|0|−1(+1U)

3.2E-02

down

−1.57

hsa-miR-27b-3p|0|0(+1U)

5.0E-02

down

−1.57

hsa-miR-26a-5p|0|−1

2.0E-02

down

−1.64

hsa-miR-148a-3p|0|+1

3.2E-02

down

−1.73

hsa-miR-148a-3p|0|+2

1.7E-02

down

−1.75

hsa-miR-27b-3p|0|−1

2.7E-02

down

−1.78

hsa-miR-23b-3p|+3|−2

6.8E-03

down

−1.87

hsa-miR-148a-3p|0|0(+1U)

1.2E-02

down

−1.90
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Table 3. Cont.
Mature miRNAs Differently Expressed in FFPE Samples: CM vs. BN
Name

p Value (Corr)

Regulation

Log FC

isomiRs
hsa-miR-26a-5p|0|0(+2U)

1.6E-04

down

−2.06

hsa-miR-27a-3p|0|−2

3.1E-03

down

−2.10

hsa-miR-101-3p|0|0(+1U)

2.7E-03

down

−2.12

hsa-miR-30e-5p|0|+1

4.8E-04

down

−2.35

hsa-miR-141-3p|0|−1

3.8E-03

down

−2.36

hsa-miR-30d-5p|0|−1

8.5E-03

down

−2.46

hsa-miR-99b-5p|0|−1

1.1E-02

down

−2.53

hsa-miR-199a-5p|0|−1

6.1E-06

down

−2.79

hsa-miR-27a-3p|0|−1

1.3E-03

down

−2.81

hsa-miR-19b-3p|0|−1

2.6E-04

down

−3.02

hsa-miR-101-3p|0|+1

3.4E-05

down

−3.15

hsa-miR-27b-3p|0|−2

3.4E-05

down

−3.23

hsa-miR-100-5p|0|−1

1.3E-03

down

−3.50

hsa-miR-27b-3p|0|+1

4.7E-06

down

−3.51

hsa-miR-27a-3p|0|−3

9.6E-07

down

−3.89

hsa-miR-27b-3p|0|−1(+1U)

1.2E-06

down

−3.95

hsa-miR-101-3p|−1|−1

1.2E-06

down

−4.70

hsa-miR-29a-3p|0|−1

4.0E-08

down

−5.79

In most cases, variant isoforms show the same expression variation than the canonical
miRNA, namely isomiR(s) and the corresponding canonical miRNA are all upregulated or
downregulated in the melanoma group compared to the benign nevi group. However, we
found some isomiRs of the same canonical miRNA that present opposite trends. Specifically,
miR-30d-5p and miR-30a-5p have isomiRs with reverse trends: miR-30a-5p|0|+2 and
miR-30d-5p|0|+2 are upregulated in early-stage melanoma, while miR-30a-5p|0|−1, miR30a-5p|0|−2 and miR-30d-5p|0|−1 are downregulated compared to benign nevi samples.
Canonical miRNAs of miR-30a-5p and miR-30d-3p are not differentially expressed between
CM and BN.
Among the 37 isomiRs that are differently expressed in early-stage CM vs. BN, there
are 16 miRNAs with a ratio isomiR/miRNA > 1 (Table 2). In particular, hsa-miR-1013p|0|+1, hsa-miR-101-3p|0|0(+1U), hsa-miR-101-3p|−1|−1, hsa-miR-141-3p|0|−1, hsamiR-19b-3p|0|−1, hsa-miR-27a-3p|0|−1, hsa-miR-27a-3p|0|−2, hsa-miR-27b-3p|0|−1,
hsa-miR-29a-3p|0|−1, hsa-miR-30a-5p|0|−1, hsa-miR-30a-5p|0|−2, and hsa-miR-30d5p|0|−1 are downregulated in early-stage CM, while hsa-miR-203a-3p|+1|0(+1U), hsamiR-222-3p|0|+3, hsa-miR-30a-5p|0|+2, and hsa-miR-30d-5p|0|+2 are upregulated in
early-stage CM (Tables 2 and 3).
2.5. Classification of isomiRs with a Potentially Relevant Role in Early-Stage Melanoma
We decided to further investigate the expression of mature miRNAs in FFPE samples
showing two characteristics: (i) at least one isoform is differentially expressed between
early-stage CM and BN and (ii) at least one isoform is more expressed than the canonical
form. We obtained a list of 10 miRNAs, which were further divided into four classes: (a)
isomiRs with a similar trend in early-stage CM vs. BN and similar relative abundance; (b)
isomiRs with a similar trend in early-stage CM vs. BN and different relative abundance; (c)
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isomiRs with opposite trend in early-stage CM vs. BN and similar relative abundance; and
(d) isomiRs with opposite trend in early-stage CM vs. BN and different relative abundance.
2.5.1. IsomiRs with a Similar Trend in Early-Stage CM vs. BN and Similar
Relative Abundance
The first class includes canonical miRNAs and corresponding isomiRs with the same
trend of variation between early-stage CM and BN and a similar abundance distribution.
miR-19b-3p, miR-27a-3p, miR-29a-3p and miR-222-3p belong to this class. The first three
canonical miRNAs and their isomiRs are downregulated in CM, while mature microRNAs
of miR-222-3p are upregulated in CM (Figure 3A–C). Also the relative abundance is similar
in CM and BN. In fact, both in CM and BN the most expressed isomiRs are miR-19b3p|0|−1, 27a-3p|0|−1, miR-29a-3p|0|−1 followed by the canonical miR-29a-3p and
miR-222-3p|0|+3 (Figure 3).

Figure 3. Group 1: IsomiRs with a similar trend in 20 FFPE CM vs. 3 FFPE BN and similar relative abundance. (A) Mature
microRNA expression in BN and CM. All mature microRNAs are represented in a separated bar chart (mean ± standard
deviation). A Mann-Whitney test was performed to compare the expression level in BN and CM. P values are shown when
the difference is statistically significant. (B) Expression trend of mature microRNAs in BN and primary CM. Before-after blot
shown the same expression trend between mature microRNAs. (C) Mature microRNA abundance distribution microRNAs
in BN and CM. Stacked bar chart illustrates the same mature microRNA abundance distribution between BN and CM.
Mature microRNAs are sorting based on their expression in BN.
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2.5.2. IsomiRs with a Similar Trend in CM vs. BN and Different Relative Abundance
The second class is formed by miRNAs with the same trend of variation for all their
isomiRs in CM vs. BN, but with different abundance distribution between CM and BN.
miR-101-3p and miR-27b-3p belong to this class. Almost all variants and canonical miR101-3p have a significantly lower expression in CM (Figure 4A,B). Mature microRNAs of
miR-101-3p are not distributed in the same way in CM and BN, though. As represented
in Figure 4C, we can observe that the major expressed isomiR is miR-101-3p|0|0(+1U) in
CM and miR-101-3p|−1|−1 in BN. All 9 isomiRs and canonical form of miR-27b-3p are
downregulated in CM compared to BN with a significant difference in most of the cases
(Figure 4A,B). Focusing on abundance distribution of the different variants and canonical
miRNA, we observed that miR-27b-3p|0|−1 is the most expressed form in CM, while the
canonical miRNA is the most expressed mature miRNA in BN (Figure 4B,C).

Figure 4. Group 2: IsomiRs with a similar trend in 20 CM vs. 3 BN and different relative abundance. (A) Mature microRNA
in BN and CM. All mature microRNAs are represented in a separated bar chart (mean). Bar indicates standard deviation.
Mann-Whitney t test was performed to compared expression level in BN and CM. p values are shown when the difference
is statistically significant. (B) Expression trend of mature microRNAs in BN and CM. Before-after blot shown the same
expression trend between mature microRNAs. (C). Mature microRNA abundance distribution in BN and CM. A stacked
bar chart illustrates a different mature microRNA abundance distribution between BN and CM. Mature microRNAs are
sorting based on their expression in BN.

2.5.3. IsomiRs with Opposite Trend in CM vs. BN and Similar Relative Abundance
The only miRNA of the third class is miR-141-3p. This isomiR is downregulated in
CM compared to BN (miR-141-3p|0|−1, p value = 0.0023), but the canonical miRNA and
miR-141-3p|0|+1 have a comparable expression in CM and BN. miR-141-3p|0|+2 is only
detectable in CM samples (Figure 5A,B). The abundance distribution is similar between
CM and BN, in fact miR-141-3p|0|−1 isomiR is the most expressed mature microRNA in
both groups (Figure 5C).
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Figure 5. Group 3: IsomiRs with opposite trends in 20 CM vs. 3 BN and similar relative abundance. (A) Mature microRNA
expression in BN and CM. All mature microRNAs are represented in a separated bar chart (mean). Bar indicates standard
deviation. Mann-Whitney t test was performed to compared expression level in BN and CM. p values are shown when the
difference is statistically significant. (B) Expression trend of mature microRNAs in BN and CM. Before-after blot shown a
different expression trend between mature microRNAs. (C) Mature microRNA abundance distribution in BN and CM. The
stacked bar chart illustrates the same mature microRNA abundance distribution between BN and CM. Mature microRNAs
are sorting based on their expression in BN.

2.5.4. IsomiRs with Opposite Trend in CM vs. BN and Different Relative Abundance
The last class comprises three miRNAs, namely miR-30a-5p, miR-30d-5p and miR203a-3p, which show different isomiRs abundance distribution in CM and BN and a
different expression trend between isomiRs and the canonical form (Figure 6A–C).
In the case of miR-30a-5p, we identified six different isomiRs that are expressed in CM
and BN. The most expressed variant in CM is miR-30a-5p|0|+2, while in BN is miR-30a5p|0|−2 (Figure 6C). Looking at variants that are differently expressed between CM and
BN, we noticed that one is upregulated (miR-30a-5p|0|+2), while two are downregulated
(miR-30a-5p|0|−1, miR-30a-5p|0|0(+1U)) in CM (Figure 6A,B).
Also miR-30d-5p have six detected isomiRs. One of the isomiRs is detected only in
CM (miR-30d-5p|0|+2(+1U)), and the canonical form and several isomiRs do not show
differences between CM and BN. However, there are two isomiRs that have a significant
and opposite trend: miR-30d-5p|0|−1 is under expressed in CM, while miR-30d-5p|0|+2
is overexpressed in CM (Figure 6A,B). Moreover, miR-30d-5p|0|−1 and miR-30d-5p|0|+2
are also the most expressed isomiR in CM and BN, respectively (Figure 6C).
Looking at the expression trend in CM and BN of the nine isomiRs of miR-203a3p, only three of them have different expression. MiR-203a-3p|0|−1 and miR-203a3p|0|+1 are downregulated in CM, while miR-203a-3p|+1|0(+1U) is upregulated in CM
(Figure 6A,B). Furthermore, isomiR abundance distribution is different. In fact, the most
expressed variant in BN is miR-203a-3p|0|+1, while in CM is miR-203a-3p|+1|0(+1U)
(Figure 6C).
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Figure 6. Group 4: IsomiRs with the opposite trend in 20 CM vs. 3 BN and different relative abundance. (A) Mature
microRNA expression in BN and CM. All mature microRNAs are represented in a separated bar chart (mean). Bar indicates
standard deviation. A Mann-Whitney t test was performed to compared expression level in BN and CM. p values are shown
when the difference is statistically significant. (B) Expression trend of mature microRNAs in BN and CM. Before-after blot
shown a different expression trend between mature microRNAs. (C) Mature microRNA abundance distribution in BN and
CM. The stacked bar chart illustrates a different mature microRNA abundance distribution between BN and CM. Mature
microRNAs are sorting based on their expression in BN.

2.6. IsomiR Classification in Fresh-Frozen Primary Melanoma and Metastasis
from TCGA Database
In order to identify isomiRs potentially associated with tumor progression, we interrogated the SKCM cohort of The Cancer Genome Atlas (TCGA) database. The TCGA
database collects clinical and molecular data from fresh-frozen tissues, including smallRNA
seq data. We explored the contribution of isomiRs in 323 melanoma patients, including 63
primary cutaneous melanomas (CM), and 260 melanoma metastases (MM), and assessed
the association of isomiR expression with melanoma mutated genes. We detected a total of 3690 mature microRNAs, including 474 canonical microRNAs and 3216 isomiRs
(Supplementary Table S4). Among the canonical miRNAs, only 85 miRNAs did not have
any detected isomiR, while 389 canonical microRNAs had at least one co-expressed isomiR.
Again, we observed the presence of orphan isomiRs (n = 258). However, for the majority of
isomiRs, the canonical forms are detectable (n = 2958). The classification in isomiR types is
reported in Table 4. The most frequent isomiR group is the end-site type. Interestingly, in
this isomiRs list we showed the presence of a 50 non-templated addition group, namely
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isomiRs with the addition of one or more nucleotides in the 50 end, which did not match
with the stem-loop sequence.
Table 4. Mature microRNA classification in 323 Fresh-frozen Melanoma from TCGA SKCM cohort.
Mature miRNAs and Novel miRNAs from TCGA
Type
”canonical” miRNAs

isomiRs

novel miRNAs

isomiRs of novel miRNAs

Sub-type

Total

miRNA with isomiR

389 (10.52%)

miRNA without isomiR

85 (2.30%)

isomiR with canonical miRNA

2958 (80.01%)

orphan isomiR

258 (6.97%)

with isomiR

1 (0.03%)

without isomiR

3 (0.08%)

with novel miRNA

1 (0.03%)

without novel miRNA

2 (0.06%)

474 (12.82%)

3216 (86.98%)

4 (0.11%)

3 (0.09%)

Total

3697 (100%)
IsomiR classification

Groups

30

Sub-groups

End-site isomiRs

1271 (39.52%)

1271 (39.52%)

Start-site isomiRs

341 (10.60%)

341 (10.60%)

Shifted isomiRs

187 (5.82%)

187 (5.82%)

206 (6.41%)

206 (6.41%)

3 (0.09%)

3 (0.09%)

non-templated addition
isomiRs

50 non-templated addition
isomiRs
start-site + end-site
30

Mixed isomiRs

start-site + non-templated
addition
30

Total

Total

510 (15.86%)
84 (2.61%)

end-site + non-templated
addition

465 (14.46%)

start-site + end-site + 30
non-templated addition

94 (2.92%)

50 non-templated addition +
end-site

9 (0.28%)

shifted + 30 non-templated
addition

46 (1.43%)

1208 (37.56%)

3216 (100%)

In addition, we found four novel miRNAs and three isomiRs of novel miRNAs. These
novel miRNAs have been previously detected by examining small RNA-seq samples [28]
(Supplementary Table S4).
2.7. Identification of the isomiRs More Expressed Than the Canonical Form in Fresh Primary
Melanoma Samples from TCGA
To identify the most abundant isomiRs in fresh-frozen melanomas we investigated
isomiRs that showed a higher or an equal expression level than the corresponding canonical
mRNA form in primary melanomas from the TCGA SKCM cohort, which includes mostly
stage II and stage III fresh primary melanoma.
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We considered the average expression of mature microRNAs in 63 CM and we calculated the expression ratio between 2958 isomiRs and the corresponding canonical miRNA.
We obtained a wide set of ratios that are reported in Supplementary Table S5, and 1373 of
them showed a ratio higher than 1. Among these 1373 isomiRs, there were also 21 of the
isomiRs identified in early-stage FFPE melanomas (mostly stage I melanomas) reported in
Table 2, confirming the identification of these isomiRs also in fresh melanoma tissue and
late-stage melanomas (Table 5).
Table 5. List of isomiRs with an isomiR/canonical miRNA ratio greater than 1 in 63 fresh-frozen and
20 FFPE primary melanoma samples at different stages.

Mature microRNA Name

Ratio isomiR/Canonical
miRNA in 63 Late-Stage
CM Samples

Ratio isomiR/Canonical
miRNA in 20 Early-Stage
CM Sample

hsa-miR-101-3p|0|0(+1U)

1.21

2.22

hsa-miR-125a-5p|0|−2

2.22

10.35

hsa-miR-141-3p|0|−1

506.45

30.01

hsa-miR-142-5p|−2|−3

137.60

1.28

hsa-miR-146b-5p|0|+1

2.68

1.07

hsa-miR-199a-3p|0|−1

5.22

4.89

hsa-miR-199a-3p|−1|−1

1.14

1.66

hsa-miR-200b-3p|0|+1

2.41

10.39

hsa-miR-200b-3p|0|+1(+1U)

67,983.34

7.76

hsa-miR-203a-3p|+1|0(+1U)

16.12

1.99

hsa-miR-203a-3p|0|+1

6.59

1.40

hsa-miR-222-3p|0|+3

3.80

53.84

hsa-miR-222-3p|0|+4

57.90

15.25

hsa-miR-26b-5p|0|+1

15.51

4.61

hsa-miR-27a-3p|0|−1

2.53

4.08

hsa-miR-27a-3p|0|−2

1.68

1.02

hsa-miR-27b-3p|0|−1

522.43

2.29

hsa-miR-29a-3p|0|−1

9.61

1.57

hsa-miR-30c-5p|0|+1

18.70

9.81

hsa-miR-30d-5p|0|−1

1.37

1.15

hsa-miR-30d-5p|0|−2

33.78

1.55

2.8. IsomiR Expression Contributes to Distinguish Primary Melanoma and Metastasis
We compared the mature microRNA profile of 63 fresh-frozen CM and 260 MM
samples from the TCGA database using an unpaired t-test (Benjamini-Hochberg correction,
fold change > 1.5, adjusted p value < 0.05). We obtained a list of 332 mature microRNAs
differentially expressed between the two groups. Specifically, 121 are downregulated and
211 are upregulated in MM vs. CM (Supplementary Figure S1, Supplementary Table S6).
As for the type of mature miRNAs, 36 are canonical miRNAs, while the remaining 296 are
isomiR variants. The most representative isomiR type is end-site group with 175 miRNA
variants. Other isomiRs belong to start-site (27), 30 non-templated addition (17), shifted (7).
The remaining 70 are mixed isomiRs, specifically, 37 isomiRs that differentiate from the
canonical form in the start-site and end-site; 29 in the end-site and 30 non-template addition,
3 start-site and 30 non-template addition, and 1 present different start-site, end-site and 30
non-template addition.
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Some isomiR variants show an opposite trend in CMs and MMs than their canonical
miRNA. Specifically, miR-101-3p, miR-146b-3p, miR-148a-3p, miR-15a-5p, miR-16-5p, miR181a-2-3p, miR-181a-5p, miR-181b-5p, miR-21-5p, miR-22-3p, miR-23a-5p, miR-23b-3p,
miR-24-3p, miR-30e-5p, miR-361-3p, and miR-500a-3p have at least two variants with
opposite trends (Supplementary Table S5, Supplementary Figure S2).
MMs have an upregulated isomiR (miR-146b-3p|0|−1) and a downregulated isomiR
(miR-146b-3p|−1|−2) of miR-146b-3p. Similarly, also for miR-15a-5p, miR-16-5p and miR181a-5p there is an upregulated isomiR (miR-15a-5p|0|−2, miR-16-5p|0|−2, miR-181a5p|0|−3, respectively), and a downregulated isomiR (miR-15a-5p|0|+2, miR-16-5p|0|+3,
miR-181a-5p|0|+2, respectively).
miR-148a-3p presents several differentially expressed isomiR variants, of which five
are upregulated: (miR-148a-3p|+1|0, miR-148a-3p|+1|−1, miR-148a-3p|0|−1, miR-148a3p|0|−2, and miR-148a-3p|0|−3), and two are downregulated (miR-148a-3p|0|+2, miR148a-3p|0|0(+2U)) in MM compared to CM. Two upregulated isomiRs of miR-361-3p (miR361-3p|0|−2, miR-361-3p|0|−3) and two downregulated isomiRs (miR-361-3p|+1|+2,
miR-361-3p|0|+2) have been found in MM compared to CM.
Most of the mature microRNAs of miR-181a-2-3p and miR-181b-5p are downregulated
in MM (miR-181a-2-3p|0|+1, miR-181a-2-3p|−1|0, miR-181a-2-3p|−1|−1; miR-181b5p|0|+1, miR-181b-5p|0|+2(+1U), miR-181b-5p|0|0), while only one is upregulated
(miR-181a-2-3p|0|−3, miR-181b-5p|0|−3). Similarly, miR-23b-3p and miR-500a-3p have
only one upregulated mature microRNA (miR-23b-3p|0|−4, miR-500a-3p|−1|−3), while
the others are downregulated in MM (miR-23b-3p|+1|0, miR-23b-3p|+1|0(+1U), miR-23b3p|0|0, miR-23b-3p|0|0(+1U), miR-23b-3p|0|−1(+1U), miR-23b-3p|0|−1(+2U); miR500a-3p|0|+1(+1U), miR-500a-3p|−1|+1, miR-500a-3p|−1|0, miR-500a-3p|−1|−4).
On the other hand, for miR-21-5p, miR-22-3p, miR-24-3p and miR-30e-5p there are
mostly upregulated isomiRs (miR-21-5p|+2|0, miR-21-5p|+4|0, miR-21-5p|0|−2, miR21-5p|0|−3, miR-21-5p|0|−4; miR-22-3p|+2|0, miR-22-3p|0|−2, miR-22-3p|0|−3,
miR-22-3p|0|−4; miR-24-3p|0|−3, miR-24-3p|0|−3(+1U); miR-24-3p|0|−4, miR-30e5p|+1|−2, miR-30e-5p|0|−2, miR-30e-5p|0|−3) and only one downregulated (miR-215p|0|+2, miR-22-3p|0|+1(+1U), miR-24-3p|0|0(+2U), miR-30e-5p|+1|+4, respectively)
in MM compared with CM. Three isomiR variants of miR-101-3p are differently expressed.
Specifically, miR-101-3p|0|−2 and miR-101-3p|−1|−2 are upregulated, while miR-1013p|0|0(+2U) is downregulated in MM compared to CM. In addition, miR-23a-3p presents
three upregulated isomiRs (miR-23a-3p|+1|−1, miR-23a-3p|0|−2, miR-23a-3p|0|−3)
and two downregulated isomiRs (miR-23a-3p|0|+1(+2U), miR-23a-3p|0|+2(+1U)).
2.9. Identification of isomiRs Associated with Driver GeneMutations in TCGA Samples
We obtained the mutation status of BRAF, NRAS and NF1 for the melanoma samples
from the TCGA database. We reported the mutation status of the three genes (when this
information was available), in Supplementary Table S7. The most frequent mutation in
BRAF is the missense mutation V600E, which is present in 145 samples. Among these 145
samples, 21 samples have also the mutation V600M. NRAS mutations are mostly missense
mutation in Q61- position. Specifically, we found 33 samples with Q61R, 28 samples with
Q61K, 11 samples with Q61L and five samples with Q61H.
NF1 presents a wide variety of different mutations and different types of mutations,
including missense, stop codon, frameshift, and splice mutations. We analyzed the isomiR
differential expression in mutated NF1, BRAF and NRAS compared to wild type samples.
2.9.1. Identification of Mature microRNAs Associated with Mutated NF1
The NF1 mutation status was available for 66 melanoma samples: 51 patients presented at least one mutation in NF1, and 15 patients had wild type NF1. Comparing the
mature microRNA expression in melanomas with NF1mut vs. NF1wt (t Test unpaired
unequal variance (Welch), adjusted p value < 0.1), we found a list of five differentially
expressed mature microRNAs (Table 6).
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Table 6. List of mature microRNAs associated with NF1 mutation in TCGA SKCM samples.
Comparison between NF1 Mutated and NF1 WT Samples
Type

p (Corr) (Mutated
NF1 vs. Wild
Type NF1)

Regulation (Mutated
NF1 vs. Wild
Type NF1)

Log FC (Mutated NF1
vs. Wild Type NF1)

ACTCCAGCCCCACAGCCTCA

end-site

7.77E-02

up

1.17

ATTATGGTTTGCCTGGGACTG

mixed: start-site
+ end-site

8.38E-02

up

1.46

mixed: shifted +
30 non-templated
addition

7.77E-02

down

−1.35

Name

Sequence

hsa-miR-766-3p|0|−2
hsa-miR-5845p|−1|−2
hsa-miR-378a3p|−1|−1(+1U)

CACTGGACTTGGAGTCAGAAGGT

hsa-let-7d-5p|+1|−1

GAGGTAGTAGGTTGCATAGT

mixed: start-site
+ end-site

9.29E-02

up

0.70

hsa-miR-148a3p|+3|−1

GTGCACTACAGAACTTTG

mixed: start-site
+ end-site

7.77E-02

up

1.03

2.9.2. Identification of Mature microRNAs Associated with Mutated BRAF
Among 187 samples that were tested for BRAF mutations, 19 samples had no BRAF
mutations and 168 samples had at least one mutation in BRAF. The most frequent mutation
of BRAF is in position V600- (149 patients): V600E (118), V600E + V600M (21), V600M +
V600G (3), V600E + V660V (2), V600E + other mutations (5). We investigated the association
between isomiR expression and BRAF mutation, comparing mutated vs. wild type BRAF.
We found a list of 44 mature microRNAs differentially expressed. Specifically, two isomiRs
are downregulated (hsa-miR-181a-2-3p|0|+1, hsa-miR-92a-3p|0|+1(+1U)), while the
remaining 42 are upregulated in BRAF mutated melanoma patients (Table 6).
We identified the mature microRNAs that are specifically altered in BRAF (V600E)
melanoma (Table 7). Interestingly, melanomas with exclusively V600E mutation and
melanomas with both V600E and V600M BRAF mutations present 7 differentially expressed
mature microRNAs. Specifically, V600E|V600M BRAF mutated melanomas downregulated
let-7b-3p|0|−1(+1U), miR-100-5p|0|0(+1U), miR-125b-5p|0|0, miR-221-3p|0|−1, and
upregulated let-7a-5p|+1|−2, miR-1247-5p|0|−1, miR-219a-1-3p|0|0 compared to V600E
BRAF mutated melanomas.
Table 7. List of mature microRNAs associated with BRAF mutation in TCGA SKCM samples.
IsomiRs Differentially Expressed in Mutated vs. Wild Type (WT) BRAF Melanoma Samples
Name

Sequence

Type

p (Corr) (mutated
BRAF vs. WT)

Regulation FC
(mutated BRAF
vs. WT)

Log FC (mutated
BRAF vs. WT)

hsa-let-7d3p|0|−2(+2U)

CTATACGACCTGCTGCCTTTTT

mixed: end-site + 30
non-templated addition

4.40E-02

up

0.76

hsa-let-7i-3p|0|−2

CTGCGCAAGCTACTGCCTTG

end-site

2.12E-02

up

1.75

hsa-miR-100-5p|+1|−1

ACCCGTAGATCCGAACTTGT

mixed: start-site +
end-site

2.14E-02

up

1.96

hsa-miR-100-5p|0|−1

AACCCGTAGATCCGAACTTGT

end-site

2.02E-02

up

2.00

hsa-miR-1005p|0|−1(+2U)

AACCCGTAGATCCGAACTTGTTT

mixed: end-site + 30
non-templated addition

7.63E-07

up

1.39

hsa-miR-106b3p|+1|−1

CGCACTGTGGGTACTTGCTG

mixed: start-site +
end-site

4.49E-03

up

0.81

hsa-miR-1247-5p|0|−1

ACCCGTCCCGTTCGTCCCCGG

end-site

2.02E-02

up

0.96

hsa-miR-125b-5p|0|+1

TCCCTGAGACCCTAACTTGTGAG

end-site

2.44E-04

up

0.86

hsa-miR-1307-3p|0|−2

ACTCGGCGTGGCGTCGGTCG

end-site

3.05E-02

up

0.80

hsa-miR-1433p|0|−3(+1U)

TGAGATGAAGCACTGTAGT

mixed: end-site + 30
non-templated addition

3.95E-02

up

1.06

hsa-miR-1433p|−1|−1

CTGAGATGAAGCACTGTAGCT

shifted

4.64E-02

up

1.03

hsa-miR-1433p|−1|−3

CTGAGATGAAGCACTGTAG

mixed: start-site +
end-site

2.59E-02

up

1.21

hsa-miR-146a-5p|0|−4

TGAGAACTGAATTCCATG

end-site

3.11E-02

up

0.87
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Table 7. Cont.
IsomiRs Differentially Expressed in Mutated vs. Wild Type (WT) BRAF Melanoma Samples
Name

Sequence

Type

p (Corr) (mutated
BRAF vs. WT)

Regulation FC
(mutated BRAF
vs. WT)

Log FC (mutated
BRAF vs. WT)

hsa-miR-154-5p|0|0

TAGGTTATCCGTGTTGCCTTCG

canonical

8.45E-03

up

0.94

hsa-miR-181a-23p|0|+1

ACCACTGACCGTTGACTGTACCT

end-site

2.17E-02

down

−1.57

hsa-miR-181c-5p|0|0

AACATTCAACCTGTCGGTGAGT

canonical

8.45E-03

up

1.07

hsa-miR-199a3p|+3|−1

GTAGTCTGCACATTGGTT

mixed: start-site +
end-site

4.49E-03

up

0.82

hsa-miR-204-5p|0|0

TTCCCTTTGTCATCCTATGCCT

canonical

1.91E-02

up

1.95

2.46E-02

up

0.87

30

hsa-miR-2045p|0|0(+2U)

TTCCCTTTGTCATCCTATGCCTTT

hsa-miR-204-5p|0|−1

TTCCCTTTGTCATCCTATGCC

end-site

1.40E-02

up

2.09

hsa-miR-204-5p|0|−2

TTCCCTTTGTCATCCTATGC

end-site

1.60E-02

up

1.76

hsa-miR-214-5p|+1|0

GCCTGTCTACACTTGCTGTGC

start-site

2.59E-02

up

0.96

hsa-miR-296-3p|0|−2

GAGGGTTGGGTGGAGGCTCT

end-site

3.53E-05

up

0.98

hsa-miR-29a3p|0|−4(+2U)

TAGCACCATCTGAAATCGTT

mixed: end-site + 30
non-templated addition

4.15E-03

up

0.85

hsa-miR-30c-2-3p|0|−2

CTGGGAGAAGGCTGTTTACT

end-site

1.39E-02

up

0.72

hsa-miR-330-5p|0|−1

TCTCTGGGCCTGTGTCTTAGG

end-site

2.54E-02

up

0.78

TCTCACACAGAAATCGCACCCGTT

30 non-templated
addition

4.49E-03

up

0.70

GGGGTGCTATCTGTGATTGAGG

mixed: start-site +
end-site

1.09E-02

up

0.61

hsa-miR-381-3p|0|0

TATACAAGGGCAAGCTCTCTGT

canonical

2.52E-02

up

0.94

hsa-miR-409-5p|0|0

AGGTTACCCGAGCAACTTTGCAT

canonical

4.97E-02

up

0.93

hsa-miR-423-5p|0|−2

TGAGGGGCAGAGAGCGAGACT

end-site

2.54E-02

up

1.06

hsa-miR-4325p|0|−1(+1U)

TCTTGGAGTAGGTCATTGGGTGT

mixed: end-site + 30
non-templated addition

4.64E-02

up

1.00

hsa-miR-485-3p|0|0

GTCATACACGGCTCTCCTCTCT

canonical

3.05E-02

up

0.90

hsa-miR-3423p|0|0(+1U)
hsa-miR-342-5p|+1|+2

non-templated
addition

hsa-miR-493-3p|0|−1

TGAAGGTCTACTGTGTGCCAG

end-site

9.25E-03

up

0.92

hsa-miR-495-3p|0|0

AAACAAACATGGTGCACTTCTT

canonical

8.45E-03

up

0.89

hsa-miR-518a-3p|0|0

GAAAGCGCTTCCCTTTGCTGGA

canonical

1.91E-02

up

2.55

hsa-miR-519a5p|−1|−1

ACTCTAGAGGGAAGCGCTTTCT

shifted

2.44E-04

up

3.59

hsa-miR-6253p|+1|−1(+1U)

ACTATAGAACTTTCCCCCTCT

mixed: start-site +
end-site + 30
non-templated addition

3.90E-02

up

0.85

hsa-miR-671-3p|0|0

TCCGGTTCTCAGGGCTCCACC

canonical

3.95E-02

up

0.84

hsa-miR-6892-5p|0|−1

GTAAGGGACCGGAGAGTAGG

end-site

2.44E-04

up

0.89

TGGTTGACCAGAGAGCACACG

mixed: start-site +
end-site

1.90E-03

up

0.91

2.14E-02

down

−1.31

hsa-miR-758-5p|+2|+1

30

mixed: end-site +
non-templated addition

hsa-miR-92a3p|0|+1(+1U)

TATTGCACTTGTCCCGGCCTGTGT

hsa-miR-937-3p|0|−2

ATCCGCGCTCTGACTCTCTG

end-site

6.44E-03

up

1.09

hsa-miR-942-5p|0|−2

TCTTCTCTGTTTTGGCCATG

end-site

7.63E-07

up

0.93

Comparison between BRAF V600E and BRAF WT Samples
Name

Sequence

Type

p (Corr) ([V600E vs.
[WT])

Regulation FC
([V600E vs. [WT])

FC ([V600E vs. [WT])

hsa-let-7b-5p|0|−1

TGAGGTAGTAGGTTGTGTGGT

end-site

0.0289

up

2.13

hsa-let-7b-5p|0|−2

TGAGGTAGTAGGTTGTGTGG

end-site

0.0262

up

2.32

hsa-miR-100-5p|+1|−1

ACCCGTAGATCCGAACTTGT

mixed: start-site +
end-site

0.0234

up

4.35

hsa-miR-100-5p|0|0

AACCCGTAGATCCGAACTTGTG

canonical

0.0262

up

3.62

hsa-miR-100-5p|0|−1

AACCCGTAGATCCGAACTTGT

end-site

0.0089

up

4.59

hsa-miR-125b-5p|0|0

TCCCTGAGACCCTAACTTGTGA

canonical

0.0323

up

2.70
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Comparison between BRAF V600E and BRAF WT Samples
Name

Sequence

Type

p (Corr) ([V600E vs.
[WT])

Regulation FC
([V600E vs. [WT])

FC ([V600E vs. [WT])

hsa-miR-125b-5p|0|−1

TCCCTGAGACCCTAACTTGTG

end-site

0.0262

up

3.02

hsa-miR-146b-3p|0|0

GCCCTGTGGACTCAGTTCTGGT

canonical

0.0146

up

2.33

hsa-miR-181c-5p|0|0

AACATTCAACCTGTCGGTGAGT

canonical

0.0262

up

2.22

hsa-miR-204-5p|0|0

TTCCCTTTGTCATCCTATGCCT

canonical

0.0289

up

4.63

hsa-miR-181a-23p|0|+1

ACCACTGACCGTTGACTGTACCT

end-site

0.0241

down

−2.91

hsa-miR-181a-23p|−1|−1

AACCACTGACCGTTGACTGTAC

shifted

0.0483

down

−2.29

Comparison between BRAF V600E-V600M and BRAF V600E Samples
Name

Sequence

Type

p (Corr) ([V600E |
V600M] Vs.
[V600E])

Regulation ([V600E
| V600M] Vs.
[V600E])

FC ([V600E | V600M]
vs. [V600E])

hsa-let-7b3p|0|−1(+1U)

CTATACAACCTACTGCCTTCCT

mixed: end-site + 30
non-template addition

0.03969

down

−2.30

hsa-miR-1005p|0|0(+1U)

AACCCGTAGATCCGAACTTGTGT

30 non-template
addition

0.03969

down

−4.14

hsa-miR-125b-5p|0|0

TCCCTGAGACCCTAACTTGTGA

canonical

0.03969

down

−2.77

hsa-miR-221-3p|0|−1

AGCTACATTGTCTGCTGGGTTT

end-site

0.03969

down

−2.29

GAGGTAGTAGGTTGTATAG

mixed: start-site +
end-site

0.03969

up

2.14

hsa-let-7a-5p|+1|−2
hsa-miR-1247-5p|0|−1

ACCCGTCCCGTTCGTCCCCGG

end-site

0.03969

up

4.07

hsa-miR-219a-1-3p|0|0

AGAGTTGAGTCTGGACGTCCCG

canonical

0.03969

up

1.75

2.9.3. Identification of Mature microRNAs Associated with Mutated NRAS
In the TCGA database, 111 melanoma samples were tested for NRAS mutations. 26
melanomas have wild type NRAS, while 85 have at least one mutation in NRAS. Comparing
the mature microRNA expression in mutated and wild type NRAS, we identified six
differentially expressed mature microRNAs (Table 8).
Table 8. List of mature microRNAs associated with NRAS mutation in TCGA SKCM samples.
Comparison between Mutated NRAS and Wild Type (WT) NRAS
Name
hsa-miR-17-3p|+1|0

Sequence

Type

p (Corr)(Mutated
NRAS vs. Wild
Type NRAS)

Regulation(Mutated
NRAS vs. Wild
Type NRAS)

Log FC(Mutated NRAS
vs. Wild Type NRAS)

CTGCAGTGAAGGCACTTGTAG

start-site

8.11E-02

up

0.92

hsa-miR-17-3p|0|0

ACTGCAGTGAAGGCACTTGTAG

canonical

2.11E-02

up

0.85

hsa-miR-19b-3p|0|−1

TGTGCAAATCCATGCAAAACTG

end-site

8.11E-02

up

0.79

hsa-miR-20a-5p|0|−2

TAAAGTGCTTATAGTGCAGGT

end-site

7.26E-02

up

0.85

hsa-miR-3614-5p|0|−1

CCACTTGGATCTGAAGGCTGCC

end-site

8.11E-02

up

0.85

hsa-miR-509-3p|+4|+1

TGGTACGTCTGTGGGTAGA

mixed: start-site +
end-site

4.66E-02

down

−1.10

3. Discussion
The miRBase database provides a single mature sequence for each miRNA, which
is usually the sequence with the highest coverage reported in small RNA sequencing
experiments. However, we discovered that in both FFPE and fresh-frozen melanoma
samples several isomiRs are more abundant than the canonical forms, being up to 50 times
more expressed in FFPE early-stage melanoma samples. We observed that end-site isomiRs
are the most represented group in FFPE and fresh melanomas. Similarly, in colon cancer it
was observed that 30 isomiRs are the most frequent microRNA variants [29].
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In the literature, there is a concern that sequencing and/or mapping artefacts may
result in an overrepresentation of isomiRs [30]. However, previous studies have shown
that isomiRs represent actual molecules rather than sequencing artifacts. First, by using
aggressive filtering, most categories of isomiRs are detected at levels above thresholds
comparable to their canonical miRNA sequence. In many cases, the isoform is present
at increased levels as compared to the canonical sequences [19]. Furthermore, various
studies have shown that isomiR profiles across tissues differ. In other words, the most
abundant isoform does differ across tissues and disease states. This suggests that isomiR
biogenesis may be a regulated process [31]. Furthermore, sequence library preparation
could cause miRNA degradation at the miRNA ends, resulting in the identification of
isomiRs. If true, these effects cannot explain the bias of the heterogeneity between the
two miRNA ends in which the 30 -ends are usually more diverse than the 50 -ends [32].
Additionally, a significant number of isomiRs are also longer and more abundant than the
canonical miRNA. These observations suggest that isomiRs are not experimental artifacts
but rather true biological events. Our sequence analysis pipeline uses isoMiRmap [27]. In
a deterministic and exhaustive manner, isoMiRmap comprehensively reports all isomiRs
whose sequences exist within known miRNA sequences. Additionally, this approach
identifies 30 -non-templated isomiRs.
Similarly to canonical miRNAs, isomiR expression can discriminate human cancers, [24]. In addition, recent studies have demonstrated that isomiRs could be used
as prognostic and diagnostic biomarkers in various cancers and related subtypes; in fact,
they can differentiate between healthy and non-healthy individuals [33]. To analyze the
contribution of isomiRs to melanoma pathogenesis, we compared the isomiR profile of
benign nevi and early-stage primary cutaneous melanoma FFPE samples, and of primary
cutaneous melanoma and melanoma metastasis of fresh-frozen samples.
A differential expression of isomiRs was observed between benign nevi and earlystage melanoma FFPE samples; specifically, 55 mature microRNAs (including the canonical
form and all isoforms) were differently expressed. Interestingly, for some miRNAs only
the isomiR(s) was differently expressed and not the canonical miRNA. Among these
55 mature microRNAs, we identified 16 isomiRs that were more abundant than their
canonical counterpart. We focused on these 16 isomiRs, which were classified in four
groups according to the expression trend in tumors and miRNA/isomiR relative abundance
distribution.
Among the mature microRNAs with similar expression trends and similar abundance
distribution in nevi and early-stage melanomas, we found miR-19b-3p, miR-27a-3p, miR29a-3p and miR-222-3p. Despite our data that showed that miR-19b-3p and its isomiR are
downregulated in early-stage FFPE melanoma, an in vitro study showed that miR-19b-3p
expression is higher in most melanoma cell lines compared with normal melanocytes, where
it promotes cell proliferation [34]. The literature suggests that melanoma tissues upregulate
miR-27a-3p and its expression is positively correlated with tumor stage and lymph node
metastasis of melanoma tissues. The downregulation of miR-27a-3p induces autophagy
and apoptosis of melanoma cells [35]. No data exist about the differential expression
of this miRNA between nevi and melanoma. We found that miR-29a-3p expression is
lower in early-stage melanoma. This data is in agreement with the literature; in fact it
was observed that the overexpression of miR-29a-3p inhibits proliferation, migration, and
invasion, and promotes apoptosis by blocking Wnt/β-catenin and NF-κB pathways [36].
The higher expression of miR-222-3p and its isomiRs in early-stage melanoma suggests an
oncogenic role, in fact miR-222-3p belongs to the miR-221 family, which is an important
oncogenic microRNA family involved in the progression of melanoma and have a key role
in EMT [37]. For this class of isomiRs, we hypothesized a cooperative effect of the isomiRs
on the target genes.
In the second class we identified miR-101-3p and miR-27b-3p mature microRNAs,
which have the same expression trend but different abundance distribution in benign nevi
and early-stage melanomas. All their mature microRNAs are downregulated in melanoma.
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These results agree with previous studies describing these two canonical miRNAs as tumor
suppressor miRNAs. miR-101-3p directly targets MITF and EZH2, resulting in inhibition
of invasion and proliferation. In addition, low expression of miR-101-3p correlated with
a poor survival in stage IV melanoma patients [38]. Canonical miR-27b-3p inhibits the
development of melanoma by targeting MYC [39].
We identified a specific isomiR of miR-141-3p, miR-141-3p|0|−1, which is downregulated in early-stage melanoma, while the canonical miRNA is not differentially expressed.
In both groups, namely benign nevi and early-stage melanoma, this specific isomiR is the
most abundant variant. This seems to suggest that only this isomiR could have a protective
role, and not the canonical form or the other variants. The canonical miRNA was found to
inhibit the proliferation of melanoma cells [40].
Our analysis revealed that miR-30a-5p, miR-203a-3p and miR-30d-5p showed a different expression trend for at least two isoforms, and a different mature microRNA prevalence
in benign nevi and early-stage melanomas. The canonical miRNAs of these isomiRs have
been extensively studied in melanoma. MiR-30a-5p is considered a tumor suppressor microRNA in melanoma. In fact, miR-30a-5p is normally downregulated in melanoma tissues
and cell lines. The overexpression of miR-30a-5p leads to a significant inhibition of proliferation, migration, and invasion of melanoma cells. Moreover, miR-30a-5p in vivo delays
tumor growth [41] and inhibits metastasis [42]. In our analysis, the canonical miR-30a-5p is
more expressed in benign nevi than early-stage melanomas, although the difference is not
statistically significant. We can speculate that the tumor suppressor effects derive from the
cumulative activity of all the isoforms.
MiR-203a-5p is an important tumor suppressor miRNA in melanoma, involved in the
regulation of proliferation, cell cycle, migration, and invasion [43,44]. The expression of
canonical miR-203a-3p is downregulated in melanoma, especially in metastatic melanoma.
Low miR-203a-3p expression is associated with poor overall survival [45]. MiR-30d-5p acts
as an oncomiR in melanoma. High expression of miR-30d-5p in melanoma is associated
with stage, metastatic potential, shorter time to recurrence, and reduced overall survival.
miR-30d-5p induces metastatic behavior of melanoma cells [46]. In this analysis, BN and
melanomas show similar expression levels of miR-203a-3p and miR-30d-5p canonical
miRNAs, which are probably linked with the early stages of the melanomas, but several
isoforms of miR-30 are significantly downregulated in tumors.
To study the isomiR contribution to melanoma progression, we took advantage of data
available from TCGA. The TCGA database provides clinical and molecular information
from fresh tumor tissues, including smallRNA sequencing data from primary melanoma
and melanoma metastasis (Skin cutaneous melanoma, SKCM). In the SKCM cohort, the
primary tumors are mostly of advanced stages (stage II and stage III). Primary melanoma
and melanoma metastasis present strong differences in the isomiR profile; in fact, 121
mature microRNAs are downregulated and 211 are upregulated in melanoma metastases
compared with primary melanomas. Among them, miR-101-3p, miR-146b-3p, miR-148a-3p,
miR-15a-5p, miR-16-5p, miR-181a-2-3p, miR-181a-5p, miR-181b-5p, miR-21-5p, miR-22-3p,
miR-23a-5p, miR-23b-3p, miR-24-3p, miR-30e-5p, miR-361-3p, and miR-500a-3p have at
least two variants with opposite trends in primary melanoma and metastasis.
Mutations in key genes of the MAPK/ERK pathway, namely NF1, NRAS and BRAF,
identify three main molecular subtypes of melanoma. Several microRNAs are known to
affect or to be affected by the altered activation of this pathway in melanoma, and some of
them are responsible for drug resistance [47]. Since the study of the expression of isomiRs
in relation to the mutation status of these proteins is missing in the literature, we focused
on the different isomiR profiles associated with the different mutation status of NF1, BRAF
and NRAS.
We collected information on the mutation status of BRAF, NRAS and NF1 genes for
SKCM TCGA samples and investigated the association between isomiR expression and the
most clinically relevant mutations in melanoma.
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Somatic mutations of BRAF gene have been found in almost 47% of sporadic cutaneous melanomas. The most frequent mutation is the V600E (56%), while other activating
mutation at codons 600 and 601, such as V600K V600R V600D K601E, were less frequent
(20%, 2%, 1%, 2% respectively). NRAS mutations were found in 28% of the tumors and
almost all of them occurred at “hotspot” codons 12, 13 or 61 (6%, 4%, 86% respectively) [48].
We identified isomiRs differentially expressed in the NF1, BRAF and NRAS mutation
groups, suggesting that the identified isomiRs could have a suppressive, promotive or
cooperative role in the MAPK pathway.
Several canonical miRNAs of isomiRs that are differently expressed in mutated BRAF
samples were already studied in relation to BRAF. It was observed that Vemurafenib, a
BRAF inhibitor, alters the miRNA expression in melanoma cells, leading to an upregulation
of miR-181a-2-3p [49]. MiR-181c-5p was found to be associated with the BRAF mutation
in thyroid follicular adenomas. Indeed, its expression is upregulated in RAS- or BRAFmutated follicular adenomas compared to wild-type tumors [50]. However, its role in
melanoma has yet to be established.
Among the miRNAs whose isoforms are associated with BRAF mutations, let-7a-5p
and let-7b-5p are well known important tumor suppressor miRNAs which are downregulated in melanoma and inhibit proliferation and migration of melanoma cells [51].
miR-143-3p acts as an inhibitor of migration and proliferation and an inducer of apoptosis in melanoma cancer cells in vitro [52]. miR-154-5p represses cell proliferation and
metastasis in melanoma [53], while miR-330-5p, miR-342-5p, and miR-942-5p inhibit cell
proliferation and invasion in cutaneous malignant melanoma [54–56].
It has been described that B-Raf/MKK/ERK can upregulate miRNAs in melanoma
cells, specifically the miR-17-92 microRNA family [57]. We observed a remarkable upregulation of several isomiRs from the miR-17-92 cluster in NRAS mutant melanomas.
IsomiR expression validation with methods other than NGS is still an open issue,
given the lack of commercial kits or largely recognized approaches. The most promising
technique to quantify miRNA variants is Dumbbell PCR. Honda et al. developed this
method to quantify specific small RNA variants with a single nucleotide resolution at
terminal sequences (50 and 30 ) [58]. In our previous work, we combined two different
commercial kits to quantify the sum of 50 and 30 isoforms and the canonical miRNA [26].
The development of reliable assays will be of the utmost importance for further functional
studies involving isomiRs.
4. Materials and Methods
4.1. FFPE Samples and Small-RNA Sequencing Data
Patients characteristics and experimental procedure are described in our previous
work [26]. In this paper, we used small-RNA sequencing data from three benign nevi (BN)
and 20 melanomas (CM).
Samples were obtained from the melanoma center of the Dermatology Unit at Bologna
University Hospital. The study was approved by Comitato Etico Indipendente di Area Vasta
Emilia Centro—CE-AVEC, Emilia-Romagna Region (number 417/2018/Sper/AOUBo).
Histopathologic specimens were evaluated by two dermato-pathologists and classified
into benign nevi and melanomas. BN includes patients with no prior diagnosis of CM or
non-melanoma skin cancer and a follow-up of at least 10 years. CM includes 19 patients with
superficial cutaneous melanoma (stage I, Breslow range = 0.3–.), and one patient with nodular cutaneous melanoma (stage II, Breslow = 2.5). Patient specimens were formalin-fixed
and paraffin-embedded (FFPE), which were used to RNA extraction using the miRNeasy
FFPE kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The 23
small-RNA libraries were generated using TruSeq Small RNA Library PrepKit v2 (Illumina,
San Diego, CA, USA, RS-200-0012/24/36/48), according to the manufacturer’s directions.
Raw base-call data were demultiplexed using an Illumina BaseSpace Sequence Hub and
converted to FASTQ format [26]. The small RNA sequencing raw data (FASTQ format)
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are available at the European Nucleotide Archive (ENA) with the following accession
number: PRJEB35819.
4.2. IsomiR Analysis of TCGA SKCM Cohort
We collected isomiR data and mutation status of BRAF, NRAS and NF1 from 323
melanoma fresh-frozen samples from The Cancer Genome Atlas (TCGA), including 63
primary cutaneous melanomas (CM) and 260 melanoma metastases. In the TCGA database,
”metastatic melanoma” refers to the metastatic tissue and not to the primary melanoma that
have metastasized. To avoid misunderstanding, we preferred to call this group melanoma
metastasis (MM), instead of metastatic melanoma. CMs are mostly II or III stage (37
samples are stage II, 19 are stage III, 3 are stage IV, and for four of them the stage was not
reported); and the biopsy site was: 58% lymph nodes, 21% connective, subcutaneous and
other soft tissues, 17% Skin and 4% other.
The NF1 mutation gene status was available for 66 melanomas (51 samples have at
least one mutation, and 15 are the wild type). BRAF mutation gene status was available
for 187 melanomas (168 have at least one mutation, 19 are wild type). NRAS mutation
gene status was available for 111 melanomas (85 have at least one mutation, while 26 are
wild type).
All detailed data of this melanoma dataset are available on National Cancer Institute
GDC Data Portal site (https://portal.gdc.cancer.gov, accessed on 1 June 2021).
4.3. IsomiR Identification
The mapping of sequence reads and isomiR quantification was performed using
the isoMiRmap tools [27]. isoMiRmap identifies and quantifies all isomiRs through the
direct processing of short RNA-sequencing datasets. Briefly, for each short RNA-sequence
dataset, the sequence reads were quality trimmed using the Cutadapt tool [59], keeping
only those reads between 18 and 26 nts in length. Each resulting read is subsequently
compared to a “lookup” table containing all possible isomiRs from miRbase release 22
hairpin sequences. All sequences are required to have exact matches to the isomiR lookup
table, after which they are then counted and quantified in read per million (RPM). This
approach identifies 50 -isomiRs, 30 -isomiRs, 50 -and-30 mixed isomiRs, as well as 30 nontemplated post-transcriptional additions. This approach was used for both those datasets
generated here and those samples represented in TCGA.
4.4. IsomiR Labeling and Classification
The annotation system developed by Loher et al. was used to label isomiRs [32].
Briefly, nomenclature indicates the name of the canonical miRNA, 50 end (start site), 30
end (end-site) and the eventual insertion of uracil of the isomiR compared to the canonical
miRNA sequence in miRBase database. Specifically, to define the start site and end site, zero
indicates the same terminus of the canonical miRNA, while positive sign (+) or negative
sign (-) followed by the number indicates the isomiR nucleotide shift in the 30 or 50 direction,
respectively, when compared with miRBase microRNA sequence. IsomiR were classified in
six different groups depending on the change from the canonical miRNA: start site isomiRs
(those isomiRs that varies in the start site with deletion or addition of nucleotides that
match with stem loop), end site isomiRs (those isomiRs that varies in the end site, with
deletion or addition of nucleotides that match with stem loop), 50 non-templated addition
isomiRs (isomiRs with addition of nucleotides at the 50 end, which do not match with stem
loop), 30 non-templated addition isomiRs (isomiRs with addition of nucleotides at the 30
that do not match with stem loop sequence), shifted isomiRs (start site and end site are
both shifted to 50 or to 30 direction, but the length of the isomiR is identical to the canonical
miRNA), and mixed isomiRs (isomiRs with more than one variation).
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4.5. Statistical Analysis
Normalized data were analyzed with GeneSpring GX software (Agilent Technologies).
Differentially expressed mature miRNAs (canonical miRNAs + isomiRs) were identified
using a fold change > 2 filter and moderated t-test (FDR 5% with Benjamini-Hochberg
correction) in benign nevi vs. melanoma comparison (small-RNA seq data). For TCGA
SKCM data, we applied a fold-change > 1.5 and t-test unpaired (FDR 5% with BenjaminiHochberg correction) in primary melanoma vs. melanoma metastasis comparison. To
analyze the association between isomiR and the melanoma-linked mutation, we performed
an unpaired t-test with unequal variance (Welch correction) (FDR 5% with BenjaminiHochberg correction). Graphpad Prism 6 (GraphPad Software, San Diego, CA, USA) was
used to perform specific isomiR comparisons using the Mann-Whitney non-parametric test.
5. Conclusions
Tumor characterization at the small RNA level, when focusing only on canonical
miRNAs, has the risk to overlook and lose important information that could improve our
understanding of cancer pathogenesis. Here, we provided a comprehensive characterization of isomiR dysregulation in benign nevi, melanoma at different stages and sources, and
melanoma metastasis. We showed that isomiRs can be more expressed than their canonical
miRNA and also that different isoforms are modulated in different and sometimes opposite
ways in normal and tumor samples, a fact that was not expected. We reported that specific
isomiRs are associated with tumor mutation status, sometimes diverging from the trend of
the canonical miRNA. Our results and observations about a non-random dysregulation of
specific isomiRs in melanoma serve as the basis for further functional studies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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miRNA ratios in 63 fresh-frozen melanoma samples from TCGA. Table S6: List of mature microRNAs
differentially expressed in melanoma metastasis compared to primary melanomas from TCGA SKCM
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to primary melanoma. Figure S2: Opposite expression trend of mature microRNAs in melanoma
metastasis and primary melanoma.
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